DUNEDIN, New Zealand, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Bladder cancer diagnostics provider, Pacific Edge Diagnostics, has been notified by Novitas1 that the LCD: Biomarkers for Oncology (L35396) ...

DUNEDIN, New Zealand, April 12, 2017 /PRNewswire/ -- Pacific Edge is proud to announce that its recent clinical study on Cxbladder Monitor's clinical performance and utility has been published in the ...

Providers using BxLink can easily access Cxbladder's suite of tests, allowing faster integration of these groundbreaking diagnostics into everyday practice. The platform's advanced capabilities ensure ...

Research Shows Pacific Edge’s Cxbladder Detect Outperforms Other Non-Invasive Bladder Cancer Diagnostics Dunedin, NZ and Hershey, PA (May 25, 2015): Newly published research demonstrates that ...

Pacific Edge Signs Agreement Extending Commercial Partnership with MidCentral District Health Board, to Encompass All Cxbladder Tests for Application Across the Clinical Pathway Cancer diagnostics ...

Newly published research demonstrates that Cxbladder out performs other non-invasive bladder cancer diagnostics, announced Pacific Edge, Ltd. The new research comparing and ranking four widely used ...

Pacific Edge (NZX:PEB), a cancer diagnostic company leading in the development and commercialisation of molecular diagnostic tests, has signed an agreement with FedMed, a national preferred provider ...

Pacific Edge Limited (NZX:PEB), a cancer diagnostics company developing and commercializing a suite of non-invasive tests for the detection and management of bladder cancer, announces today the ...

Pacific Edge, a cancer diagnostic company, has signed an agreement with FedMed, a provider network in the United States, to make Cxbladder available. The agreement provides FedMed's contracted ...

Pacific Edge Limited, a cancer diagnostics company, announces the commercial launch of the third product in the company's Cxbladder family of products, Cxbladder Monitor, in the United States.